Remove tag hybrid
article thumbnail

Grand Rounds October 6, 2023: Hybrid Studies Should Not Sacrifice Rigorous Methods (David M. Murray, PhD; Moderator: Jonathan Moyer, PhD)

Rethinking Clinical Trials

Moyer, PhD Statistician, NIH Office of Disease Prevention Slides Keywords Implementation; Study design; Hybrid; Clustered; DECIPHeR Key Points People often contest that hybrid designs are not as rigorous as they should be. However, I don’t have a great general solution for that issue at this point.

article thumbnail

A look back at the “Joint-efforts for pathogen genomics in public health surveillance” symposium

Sciensano

Thanks to the hybrid nature of the event, 90 participants could follow online in addition to the 70 participants that registered for attendance at the venue. BE READY project coordinator, Transversal activities in Applied Genomics ( TAG )). Dr. Marie-Alice Fraiture ( TAG ). Dr. Sigrid De Keersmaecker ( TAG ).

Genome 52
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

September 30, 2022: CTTI’s Digital Health Trials Hub Recommendations and Resources to Run Your Digital Health Trial (Marianne Chase, MGH, CTTI Team Lead, Jörg Goldhahn, ETH Zurich, CTTI Team Lead)

Rethinking Clinical Trials

DCTs range from near-traditional to hybrid to fully remote trials that conduct study visits away from the central study site using strategies such as tele-visits or home delivery of investigational products. Decentralized trials require novel technology and digital endpoints. Find CTTI’s recommendations and resources. pctGR, @Collaboratory1.

Trials 130
article thumbnail

Grand Rounds July 22, 2022: ACTIV-6: 1-Year Later and Trial Results for Ivermectin-400 and Inhaled Fluticasone (Susanna Naggie, MD, MHS)

Rethinking Clinical Trials

What were some early lessons learned in terms of how to reach people given the hybrid nature of the study? This was one of the reasons we gave people options about which drugs they were willing to take. It turned out that Ivermectin turned out to be a good recruitment tool. Were there concerns about having patients not associated with a site?

Trials 182
article thumbnail

Grand Rounds January 20, 2023: Collaborative Pragmatic Trials in Action: EVOLVE-MI (Mikhail Kosiborod, MD)

Rethinking Clinical Trials

– Could you talk a little bit more about hybrid data collection? Tags #pctGR, @Collaboratory1 The post Grand Rounds January 20, 2023: Collaborative Pragmatic Trials in Action: EVOLVE-MI (Mikhail Kosiborod, MD) appeared first on Rethinking Clinical Trials.

Trials 130
article thumbnail

Grand Rounds June 16, 2023: BeatPain Utah: Partnering With Community Health Centers Within a Socio-Technical Framework (Julie Fritz, PT, PhD, FAPTA; Guilherme Del Fiol, MD, PhD)

Rethinking Clinical Trials

Especially in studies involving chronic conditions, having long-term follow-up data to answer the core effectiveness question in a hybrid trial means there could be a long wait for results.

article thumbnail

IBM sells off large parts of Watson Health business

pharmaphorum

IBM said the sell-off is tagged as “a clear next step” as it focuses on its platform-based hybrid cloud and artificial intelligence strategy, but it’s no secret that Watson Health has failed to live up to its early promise.

Radiology 110